A Phase Ib Study of YY-20394 in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma
Clinical trial NCT04108325 · UNKNOWN
Trial details
- NCT number
- NCT04108325
- Sponsor
- Shanghai YingLi Pharmaceutical Co. Ltd.
- Status
- UNKNOWN
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2020-03-30
- Primary completion
- 2021-06-01
- Enrollment
- 58
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.